NKA Bio
$30klatest round · Venture round · Mar 2023 · 3 yr ago
1backers · Techstars
$1.3Mgrants · 2 grants · CORDIS
1-10team · employees, estimated range
Overview
NKA Bio was founded with a mission to improve trauma care by solving shock. The company is focused on its primary product NKA01 for Trauma Resuscitation. The early-stage pipeline in development includesprograms for septic shock, acute lung injury, and heart attack resuscitation.
Funding and backers
Total raised
$30k
3 rounds on record
Latest round
$30k
Venture round · Mar 2023 · 3 yr ago
Team
1-10
employees, estimated range
Grants
$1.3M
2 grants · CORDIS
Backers
1
Techstars
The money's age
Long since its last round
43 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 15, 2025
Won a grant $1.2M · CORDIS
Jul 1, 2024
Won a grant $73k · CORDIS
Mar 21, 2023
Raised a round Venture round $30k · SEC Form D
2023
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jul 2025 | $1.2M | — | CORDIS |
| Grant | Jul 2024 | $73k | — | CORDIS |
| Venture round | Mar 2023 | $30k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | NKA Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Lewis HibbsExecutive Officer, DirectorSEC Form D
Les JohnsonExecutive Officer, DirectorSEC Form D
Susan HibbsExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Improve resuscitation through earlier and controlled blood and fluid delivery. Hemorrhagic shock following penetrating trauma is associated…
Peroxitech is a privately held emerging biopharmaceutical company focused on the development and commercialization of a novel peptide for…
Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart…
According to the Center for Disease Control (CDC), 805,000 Americans suffered a heart attack in 2025. 200,000 of those heart attacks were…
Nema Health's online trauma therapy provides rapid relief and lasting results for PTSD. Book a free call and start treatment within days…
Explore the latest clinical evidence, case reviews and best practices for Protected PCI, AMI cardiogenic shock, right heart failure…
People
Lewis Hibbs
Executive Officer, Director
Les Johnson
Executive Officer, Director
Susan Hibbs
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
TechstarsVia a fund
4363 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Techstars Industries of the Future Accelerator Announces Class of 2024
Today, we're excited to announce the 10 startups selected for the 2024 class of the Techstars Industries of the Future Accelerator run in partnership with Oak Ridge National Laboratory, Tennessee Valley Authority, and University of Tennessee.
Read more
Report
NKA BIO Awarded 1.25M AirForce SBIR contract to advance lifesaving treatment for hemorrhagic shock
Read more
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Baltimore
United States
HQ
1-10 est. staff
2401 West Belvedere Avenue, Baltimore, MD, 21215-5216, US